argenx (ARGX) Scheduled to Post Quarterly Earnings on Thursday

argenx (NASDAQ:ARGX) is scheduled to post its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect argenx to post earnings of $0.10 per share for the quarter.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $552.88 on Wednesday. The business’s 50 day simple moving average is $536.03 and its 200-day simple moving average is $462.82. The firm has a market capitalization of $32.86 billion, a price-to-earnings ratio of -97.68 and a beta of 0.63. argenx has a 12 month low of $327.73 and a 12 month high of $571.97.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ARGX shares. JPMorgan Chase & Co. lifted their target price on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Oppenheimer raised shares of argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price for the company in a research note on Tuesday, July 23rd. Guggenheim restated a “buy” rating and issued a $585.00 target price on shares of argenx in a report on Thursday, September 26th. Raymond James reaffirmed a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research report on Thursday, October 10th. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $550.44.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.